Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : TGEN - Targeted Genetics Corporation -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (374)	11/19/2002 2:23:45 AM
From: mopgcw	Respond to of 557

Targeted Genetics Reports Reduction In Tumor Growth In Trial DOW JONES NEWSWIRES SEATTLE -- Targeted Genetics Corp (TGEN) announced its E1A tumor suppressor gene showed reduced tumor growth and some total tumor elimination in studies. Shares of Targeted Genetics recently traded at 71 cents a share, up 10 cents, or 16.6%, on Nasdaq volume of 52,190 shares. Average daily volume is 80,094 shares. In a press release Monday, Targeted Genetics, a gene therapy product company, said eight of ten mice tumor models intravenously treated with the LPD-E1A gene were tumor-free after 11 weeks. Among untreated mice, one of ten remained tumor-free. The research data, the result of a collaboration with the University of Texas M.D. Anderson Cancer Center, was published in the current issue of Cancer Research. Company Web site: targetedgenetics.com